Randy Scott will lead a new subsidiary at Genomic Health that will focus on integrating genomic data into clinical practice for patients with common and rare genetic conditions (see related story, this issue).
Scott will step down as Genomic Health's executive chairman but will remain a board member. CEO Kim Popovits will assume the role of chairman.
Scott is a founder of Genomic Health and was previously CEO of the company. He also founded Incyte, where he served in various positions including chief scientific officer; and has served as senior director of research at Invitron. He holds a BS in chemistry from Emporia State University and a PhD in biochemistry from the University of Kansas.
Genomic Health has also appointed Julian Baker to lead independent director. Baker has served on Genomic Health's board since 2001 and is a managing partner at Baker Brothers Investments. He is also a director of Incyte, Neurogen, Theravance, and Trimeris. He holds a BA in social studies from Harvard University.
Life Technologies has appointed Ronnie Andrews as president of medical sciences. Previously, he served as CEO of Clarient, where he helped integrate the company when it was acquired by GE Healthcare. He was also segment leader of GE Molecular Diagnostics. Before that, he was senior vice president of global marketing and commercial business operations at Roche Molecular Diagnostics.